Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23)

Oncogene volume 22, pages 5374–5378 (2003)Cite this article

Abstract

A distinctive subset of renal carcinomas is associated with Xp11.2 translocations and resulting TFE3 gene fusions (PRCC–TFE3, PSF–TFE3, NONO–TFE3, ASPL–TFE3), encoding related aberrant transcription factors. We report the cloning of a novel clathrin heavy-chain gene (CLTC)–TFE3 gene fusion resulting from a t(X;17)(p11.2;q23) in a renal carcinoma arising in a 14-year-old boy. The fusion transcript joined the 5′ exons of CLTC on chromosome band 17q23 to the 3′ exons of TFE3. CLTC encodes a major subunit of clathrin, a multimeric protein on cytoplasmic organelles, and is a known recurrent fusion partner of the ALK tyrosine kinase gene in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumors. The predicted CLTC–TFE3 product retains the nuclear localization and DNA-binding domains of TFE3, but lacks the multimerization domain of CLTC. The present renal tumor demonstrated morphologic and immunohistochemical features of both PRCC–TFE3 and ASPL–TFE3 carcinomas, including strong nuclear immunoreactivity for the TFE3 C-terminal and only minimal expression of epithelial proteins. However, unlike most renal carcinomas, it also focally expressed melanocytic proteins. The present report highlights the promiscuity of certain genes involved in chromosomal translocations. Further analysis of the shared features of CLTC and other TFE3 fusion partners may shed light on the essential biology of TFE3 fusion proteins.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Argani P, Antonescu CR, Couturier J, Fournet J-C, Sciot R, Debiec-Rychter M, Hutchinson B, Reuter VE, Boccon-Gibod L, Timmons CF, Hafez N and Ladanyi M . (2002). Am. J. Surg. Pathol., 26, 1553–1566.

  • Argani P, Antonescu CR, Illei PB, Lui MY, Timmons CF, Newbury R, Reuter VE, Garvin AJ, Perez-Atayde AR, Fletcher JA, Beckwith JB, Bridge JA and Ladanyi M . (2001b). Am. J. Pathol., 159, 179–192.

  • Argani P, Hawkins A, Griffin CA, Goldstein JD, Haas M, Beckwith JB, Mankinen CB and Perlman EJ . (2001a). Am. J. Pathol., 158, 2089–2096.

  • Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE and Ladanyi M . (2003). Am. J. Surg. Pathol, 27, 750–761.

  • Avery AK, Beckstead J, Renshaw AA and Corless CL . (2000). Am. J. Surg. Pathol., 24, 203–210.

  • Bjornsson J, Short MP, Kwiatkowski DJ and Henske EP . (1996). Am. J. Pathol., 149, 1201–1208.

  • Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt W, Lui MY, Colleoni GWB, Antonescu CR, Ladanyi M and Morris SW . (2001). Am. J. Pathol., 159, 411–415.

  • Clark J, Lu Y-J, Sidhar SK, Parker C, Gill S, Smedley D, Hamoudi R, Linehan WM, Shipley J and Cooper CS . (1997). Oncogene, 15, 2233–2239.

  • Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B, Wolf-Peeters C, Pauwels P, Hagemeijer A and Marynen P . (2002). Genes Chromosom. Cancer, 34, 354–362.

  • Davis IJ, His BL, Arroyo JD, Vargas SO, Yeh YA, Perez-Atayde AR, Argani P, Ladanyi M, Fletcher JA and Fisher DE . (2003). Proc. Natl. Acad. Sci. USA, 100, 6051–6056.

  • Heimann P, El Housni H, Ogur G, Weterman MAJ, Petty EM and Vassart G . (2001). Cancer Res., 61, 4130–4135.

  • Kirchhausen T . (2000). Annu. Rev. Biochem., 69, 699–727.

  • Kovacs G, Akhtar M, Beckwith JB, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, Moch H, Reuter VE, Ritz E, Roos G, Schmidt D, Srigley JR, Störkel S, van den Berg E and Zbar B . (1997). J. Pathol., 183, 131–133.

  • Ladanyi M . (2000). Am. J. Pathol., 157, 341–345.

  • Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Meindl A, Argani P, Healey JH, Ueda T, Yoshikawa H, Meloni-Ehrig A, Sorensen PHB, Mertens F, Mandahl N, van den Berghe H, Sciot R, Dal Cin P and Bridge J . (2001). Oncogene, 20, 48–57.

  • Pea M, Bonetti F, Martignoni G, Henske EP, Manfrin E, Colato C and Bernstein J . (1998). Am. J. Surg. Pathol., 22, 180–187.

  • Pérot C, Boccon-Gibod L, Bouvier R, Doz F, Fournet J-C, Fréneaux P, Vieillefond A and Couturier J . (2003). Cancer Genet. Cytogenet., (in press).

  • Sidhar SK, Clark J, Gill S, Hamoudi R, Crew AJ, Gwilliam R, Ross M, Linehan WM, Birdsall S, Shipley J and Cooper C . (1996). Hum. Mol. Genet., 5, 1333–1338.

  • Skalsky YM, Ajuh PM, Parker C, Lamond AI, Goodwin G and Cooper CS . (2001). Oncogene, 20, 178–187.

  • Smith CJ and Pearse BM . (1999). Trends. Cell. Biol., 9, 335–338.

  • Störkel S, Eble JN, Adlakha K, Amin M, Blute ML, Bostwick DG, Darson M, Delahunt B and Iczkowski K . (1997). Cancer, 80, 987–989.

  • Takebayashi K, Chida K, Tsukamoto I, Morii E, Munakata H, Arnhetter H, Kuroki T, Kitamura Y and Nomura S . (1996). Mol. Cell Biol., 16, 1203–1211.

  • Touriol C, Greenland C, Lamant L, Pulford K, Barnard F, Rousset T, Mason D and Delsol G . (2000). Blood, 95, 3204–3207.

  • Weterman MAJ, van Groningen JJ, Tertoolen L and Geurts van Kessel A . (2001). Proc. Natl. Acad. Sci. USA, 98, 13808–13813.

  • Weterman MAJ, von Groningen JJM, Jansen A and Geurts van Kessel A . (2000). Oncogene, 19, 69–74.

  • Weterman MAJ, Wilbrink M and Geurts van Kessel A . (1996). Proc. Natl. Acad. Sci., 93, 15294–15298.

  • Ybe JA, Brodsky FM, Hoffman K, Lin K, Liu S-H, Chen L, Earnest TN, Fletterick RJ and Hwang PK . (1999). Nature, 399, 371–375.

  • Ybe JA, Greene B, Liu S-H, Pley U, Parham P and Brodsky FM . (1998). EMBO J., 17, 1297–1303.

Download references

Acknowledgements

We thank Norman Barker for expert photographic assistance. This work was supported by NIH RO1 CA95785 (ML) and by the Alliance Against Alveolar Soft Part Sarcoma (ML).

Author information

Authors and Affiliations

  1. The Johns Hopkins Hospital, Baltimore, 21287, MD, USA

    Pedram Argani

  2. Memorial Sloan-Kettering Cancer Center, New York, 10021, NY, USA

    Man Yee Lui & Marc Ladanyi

  3. Institut Curie, Paris, F-75248, Cedex 05, France

    Jérôme Couturier

  4. Hôpital Edouard-Herriot, Lyon, 69437, Cedex 3, France

    Raymonde Bouvier

  5. Hôpital Sainte-Justine, Montréal, Québec, H3T 1C5, Canada

    Jean-Christophe Fournet

Authors
  1. Pedram Argani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Man Yee Lui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jérôme Couturier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Raymonde Bouvier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jean-Christophe Fournet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marc Ladanyi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc Ladanyi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Argani, P., Lui, M., Couturier, J. et al. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene 22, 5374–5378 (2003). https://doi.org/10.1038/sj.onc.1206686

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206686

Keywords

This article is cited by

Search

Advanced search

Quick links